Literature DB >> 19277948

Improving GPX activity of selenium-containing human single-chain Fv antibody by site-directed mutation based on the structural analysis.

Junjie Xu1, Jian Song, Fei Yan, Huiying Chu, Jixun Luo, Yongshan Zhao, Xu Cheng, Guimin Luo, Qingchuan Zheng, Jingyan Wei.   

Abstract

Glutathione peroxidase (GPX) is one of the important members of the antioxidant enzyme family. It can catalyze the reduction of hydroperoxides with glutathione to protect cells against oxidative damage. In previous studies, we have prepared the human catalytic antibody Se-scFv-B3 (selenium-containing single-chain Fv fragment of clone B3) with GPX activity by incorporating a catalytic group Sec (selenocysteine) into the binding site using chemical mutation; however, its activity was not very satisfying. In order to try to improve its GPX activity, structural analysis of the scFv-B3 was carried out. A three-dimensional (3D) structure of scFv-B3 was constructed by means of homology modeling and binding site analysis was carried out. Computer-aided docking and energy minimization (EM) calculations of the antibody-GSH (glutathione) complex were also performed. From these simulations, Ala44 and Ala180 in the candidate binding sites were chosen to be mutated to serines respectively, which can be subsequently converted into the catalytic Sec group. The two mutated protein and wild type of the scFv were all expressed in soluble form in Escherichia coli Rosetta and purified by Ni(2+)-immobilized metal affinity chromatography (IMAC), then transformed to selenium-containing catalytic antibody with GPX activity by chemical modification of the reactive serine residues. The GPX activity of the mutated catalytic antibody Se-scFv-B3-A180S was significantly increased compared to the original Se-scFv-B3. (c) 2009 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19277948     DOI: 10.1002/jmr.946

Source DB:  PubMed          Journal:  J Mol Recognit        ISSN: 0952-3499            Impact factor:   2.137


  4 in total

1.  Bioinformatics-led design of single-chain antibody molecules targeting DNA sequences for retinoblastoma.

Authors:  Guo-Gang Shang; Jian-Hua Zhang; Yong-Gang Lü; Jun Yun
Journal:  Int J Ophthalmol       Date:  2011-02-18       Impact factor: 1.779

Review 2.  Protein Design: From the Aspect of Water Solubility and Stability.

Authors:  Rui Qing; Shilei Hao; Eva Smorodina; David Jin; Arthur Zalevsky; Shuguang Zhang
Journal:  Chem Rev       Date:  2022-08-03       Impact factor: 72.087

3.  Pierce into Structural Changes of Interactions Between Mutated Spike Glycoproteins and ACE2 to Evaluate Its Potential Biological and Therapeutic Consequences.

Authors:  Zahra Sadat Hashemi; Mahboubeh Zarei; Shaden M H Mubarak; Anahita Hessami; Maysam Mard-Soltani; Bahman Khalesi; Alireza Zakeri; Mohammad Reza Rahbar; Abolfazl Jahangiri; Navid Pourzardosht; Saeed Khalili
Journal:  Int J Pept Res Ther       Date:  2021-12-16       Impact factor: 1.931

4.  Design of an engineered ACE2 as a novel therapeutics against COVID-19.

Authors:  Zahra Payandeh; Mohammad Reza Rahbar; Abolfazl Jahangiri; Zahra Sadat Hashemi; Alireza Zakeri; Moslem Jafarisani; Mohammad Javad Rasaee; Saeed Khalili
Journal:  J Theor Biol       Date:  2020-07-29       Impact factor: 2.405

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.